Overview

A Prospective Study of Cyclophosphamide Treatment for Idiopathic Retroperitoneal Fibrosis

Status:
Recruiting

Trial end date:
2023-02-10

Target enrollment:
0

Participant gender:
All

Summary

This prospective, interventional, controlled study is aimed to evaluate the efficacy and safety of cyclophosphamide in the treatment of idiopathic retroperitoneal fibrosis, which refers to the chronic nonspecific inflammation of retroperitoneal fascia and adipose tissue that gradually evolves into fibroproliferative disease.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Peking Union Medical College Hospital

Treatments:

Cyclophosphamide
Glucocorticoids

Criteria

Inclusion Criteria:

- age 18-75 diagnosed as IRPF. The diagnosis of idiopathic retroperitoneal fibrosis is
based on the following aspects :(1) the swelling of retroperitoneal tissue , which
seems neoplastic; (2) A large number of lymphocytes proliferated and infiltrated in
the affected tissues and organs, and tissues showed inflammation, fibrosis and
sclerosis, in which IgG4-positive cells accounted for less than 50% of plasma cells;
(3) Increased inflammatory markers, such as ESR and CRP; (4) Good response to
glucocorticoid therapy.

Exclusion Criteria:

- malignancy retroperitoneal fibrosis secondary to other diseases or drugs or abdominal
surgeries.